FDA looks at snoring/apnoea devices:
This article was originally published in Clinica
Executive Summary
The US FDA has scheduled a meeting of its Ear Nose and Throat Devices advisory panel and its Dental Products advisory panel to discuss general issues surrounding the prescription use versus the over-the-counter use of devices intended to treat snoring or mild to severe obstructive sleep apnoea. The discussion will include the role of the medical/dental provider in the diagnosis, treatment and follow-up of snoring and OSA; the ability of the patient to self diagnose and treat OSA; the types of clinical data that would be needed to support an over the counter indication and the components of adequate device labelling. The panels will not discuss continuous positive airway pressure devices and surgical treatments for sleep apnea. The meeting will take place on October 6 in Gaithersburg, Maryland
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.